CJC-1295 No DAC / Ipamorelin

CJC-1295 No DAC / Ipamorelin is a two-component research blend in the Growth Hormone & Performance category, pairing a synthetic growth-hormone-releasing-hormone (GHRH) analog (CJC-1295 without the Drug Affinity Complex) with the selective growth-hormone-secretagogue Ipamorelin. The "No DAC" designation indicates the GHRH analog lacks the albumin-binding modification, a structural difference associated in the research literature with a comparatively short circulating profile that is often characterized as more closely approximating pulsatile signaling. This blend is supplied as a lyophilized powder for laboratory and professional reference use only and is not approved by the FDA for therapeutic use.

The compound is of interest to investigators studying complementary secretagogue pathways, as the two peptides act on distinct receptor systems that are often examined together in preclinical models of growth-hormone axis signaling. All descriptions here are provided for research and professional reference; any effects discussed are observations drawn from the scientific literature, and individual results vary.

• Investigated in preclinical literature for modulation of endogenous growth-hormone secretion via combined GHRH and ghrelin-receptor pathways
• Studied in research models in relation to insulin-like growth factor-1 (IGF-1) signaling dynamics
• Examined in experimental contexts relating to pulsatile versus sustained growth-hormone release profiles
• Reported in research settings as a subject of interest in body-composition and lean-mass investigations, with the caveat that individual results vary
• Used as a reference compound in laboratory study of receptor-selective secretagogue activity and its reported effects on cortisol and prolactin in the models examined

For research and professional reference only. Typically supplied as a lyophilized powder; reconstitute with bacteriostatic water (or another sterile diluent appropriate to the protocol) by adding the diluent slowly against the vial wall and swirling gently rather than shaking, which helps preserve peptide integrity. Prior to reconstitution, store the sealed lyophilized vial refrigerated, and keep it away from heat, moisture, and direct light; cold or frozen storage of unopened lyophilized material is commonly used for longer-term holding. After reconstitution, keep refrigerated, protect from light, minimize freeze-thaw cycles, and use within the stability window established by the laboratory. Inspect for particulates or discoloration before use and discard if either is present. All clinical and experimental protocols, including reconstitution ratios, handling parameters, and any use, are determined solely by the licensed ordering provider; this is reference information only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

The proposed mechanism described in the research literature involves two complementary pathways acting on the somatotroph cells of the anterior pituitary. The CJC-1295 (No DAC) component is studied as a GHRH analog that binds the GHRH receptor and is reported to stimulate the synthesis and release of growth hormone, while its lack of the Drug Affinity Complex is associated in the literature with a shorter half-life and a release pattern characterized as more pulsatile. The Ipamorelin component is investigated as a selective agonist of the growth-hormone-secretagogue receptor (GHS-R, the ghrelin receptor), reported in research to influence growth-hormone pulse amplitude with comparatively limited effect on cortisol and prolactin in the models studied. Investigators have examined the two together for potential additive or synergistic signaling on the growth-hormone axis. These are proposed mechanisms drawn from preclinical study, not established therapeutic effects, and individual results vary.